Merck Drug Shows No Life-Extending Benefit in Head-and-Neck Cancer - Xconomy

Xconomy

Merck Drug Shows No Life-Extending Benefit in Head-and-Neck Cancer Xconomy The first immunotherapy approved in the U.S. to treat head and neck cancer has failed a big test, but it's unclear if the FDA will exercise its right to pull it from the market. Merck (NYSE: MRK) announced late Monday that its blockbuster cancer drug ... Merck immunotherapy fails to improve survival in head and neck cancerReuters Merck: Keytruda trial comes up short in head and neck cancer, but FDA approval staysSTAT Merck Provides Update on Phase 3 Study of KEYTRUDA ...Business Wire (press release) Endpoints News all 5 news articles »

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2uS7Fbg
via IFTTT